对[177Lu]Lu-PSMA-I&T原发或获得性耐药患者使用[177Lu]Lu-rhPSMA-10.1挽救治疗的经验
本文报告10例转移性去势抵抗性前列腺癌(mCRPC)患者在接受[177Lu]Lu-PSMA-I&T治疗期间出现疾病进展后,通过同情用药项目接受最多三周期[177Lu]Lu-rhPSMA-10.1(每周期7.4-8.1 GBq)挽救治疗的经验。首周期后5例(50%)血清PSA下降,3例(30%)影像学部分缓解,所有患者对额外治疗总体耐受良好。作者认为对[177Lu]Lu-PSMA-I&T治疗期间肿瘤进展的患者可能从该新型radiohybrid PSMA配体挽救治疗中获益。
要点
- 10例对[177Lu]Lu-PSMA-I&T耐药的mCRPC患者接受[177Lu]Lu-rhPSMA-10.1挽救治疗,每周期7.4-8.1 GBq,最多三周期。
- 首周期后5例(50%)血清PSA下降,3例(30%)影像学部分缓解,所有患者总体耐受良好。
- 作者认为对[177Lu]Lu-PSMA-I&T治疗期间进展的患者可能从[177Lu]Lu-rhPSMA-10.1挽救治疗中获益。
核心结论
- 在接受[177Lu]Lu-PSMA-I&T放射性配体治疗期间出现肿瘤进展的患者,可能从新型radiohybrid PSMA配体[177Lu]Lu-rhPSMA-10.1的挽救治疗中获益。
- [177Lu]Lu-rhPSMA-10.1更高的肿瘤吸收辐射剂量可能克服原发性和获得性辐射耐药。
研究设计与样本
- 报告10例晚期PSMA阳性前列腺癌患者,在接受[177Lu]Lu-PSMA-I&T治疗期间出现进展后,通过同情用药项目接受最多三周期[177Lu]Lu-rhPSMA-10.1挽救治疗(每周期7.4-8.1 GBq)。
- 评估疗效(根据PCWG3和RECIP的PSA反应)和总生存期,不良事件从首次给药开始记录。
主要发现
- 尽管在接受[177Lu]Lu-PSMA-I&T治疗期间出现进展,首周期[177Lu]Lu-rhPSMA-10.1挽救治疗后5例患者(50%)血清PSA水平下降。
- 影像学上,10例患者中3例(30%)显示部分放射学缓解。
- 5例血清PSA下降的患者中4例最初对[177Lu]Lu-PSMA-I&T治疗有反应但随后变得耐药,其余1例在[177Lu]Lu-PSMA-I&T治疗期间持续疾病进展但对[177Lu]Lu-rhPSMA-10.1立即出现反应。
- 所有患者对[177Lu]Lu-rhPSMA-10.1额外治疗总体耐受良好。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radioligand therapy is an increasingly important option for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). Radiohybrid ligands targeting prostate-specific membrane antigen (PSMA) are a novel group of theranostic radioligand therapy agents for which higher tumour absorbed radiation doses have been demonstrated compared to established PSMA ligands. Here, we report data from ten patients who were treated within a compassionate use program with the radiohybrid PSMA-ligand [177Lu]Lu-rhPSMA-10.1 after experiencing disease progression under treatment with [177Lu]Lu-PSMA-I&T. METHODS: Ten patients with advanced PSMA-positive prostate cancer who showed progression under treatment with [177Lu]Lu-PSMA-I&T received up to three cycles of rescue therapy with [177Lu]Lu-rhPSMA-10.1 (7.4-8.1 GBq per cycle). Efficacy (PSA response according to PCWG3 and RECIP) and overall survival were evaluated. Adverse events were recorded from first application. RESULTS: Despite progression with [177Lu]Lu-PSMA-I&T, after the first cycle of [177Lu]Lu-rhPSMA-10.1 rescue therapy, five patients (50%) showed a decrease in serum PSA level. In imaging, three of the ten patients (30%) showed a partial radiologic response. Four of the five patients with a decrease of serum PSA under [177Lu]Lu-rhPSMA-10.1 had initially responded to treatment with [177Lu]Lu-PSMA-I&T but had become resistant. However, the remaining patient had shown continuous disease progression during [177Lu]Lu-PSMA-I&T therapy but showed an immediate response to [177Lu]Lu-rhPSMA-10.1. The additional treatment with [177Lu]Lu-rhPSMA-10.1 was generally well tolerated by all patients. CONCLUSIONS: Patients showing tumour progression while receiving [177Lu]Lu-PSMA-I&T radioligand therapy may benefit from rescue therapy with the novel radiohybrid PSMA ligand, [177Lu]Lu-rhPSMA-10.1. Higher tumour absorbed radiation doses with [177Lu]Lu-rhPSMA-10.1 may overcome primary and acquired radiation resistance.
引用
- Gäble A, Dierks A, Rinscheid A, et al. Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T. Eur J Nucl Med Mol Imaging. 2024. PMID: 39489871. doi:10.1007/s00259-024-06959-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。